Skip to main content


nectin(for news)

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

(6 May, 2024) Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd, proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates.

nectin EIC news

Breaking news - Nectin winning the EIC funding

(18 March, 2024) Nectin Therapeutics Ltd. (" Nectin "), the parent company of Guangzhou Nectin Pharma Ltd. has been selected as one of the 42 recipients of EIC funding in the 2023 EIC Accelerator from a competitive field of 1,083 proposals and 242 companies that were reviewed.


Dr. Shuki Gleitman receives Certificates of Appreciation from Israeli Foreign Affairs

(25 Dec, 2023) Israeli Foreign Affairs Minister Mr. Eli Cohen awarded certificates of appreciation to businessmen and organizations for their contribution to Israel's foreign relations and strengthening its global position.

visionix news

New partnership between 20/20NOW and Visionix Americas

(16 Nov, 2023) Visionix USA is proud to share they recently entered a strategic alliance with 20/20NOW to help bring cost effective, in-office, quality synchronous tele-optometry comprehensive eye exams and ocular telemedicine closer to more patients throughout the United States.


Silexion Therapeutics Presented The LODER™ Phase 2 Summary Results In The 2023 ESMO Immuno-Oncology Congress

(30 Oct, 2023) Results from a multinational Phase 2 clinical study (Protact Trial) of siRNA directed against the oncogenic KRAS G12D and G12V mutations  in an extended release formulation (Loder™) was presented at the 2023 European Society for Medical Oncology (ESMO) annual congress (Abstract 1626P). 


FDA Clears CorNeat EverPatch, World's First Non-Degradable Synthetic Tissue Substitute for Ophthalmic Surgery

(8 Jun, 2023) CorNeat Vision's EverPatch utilizes EverMatrix™, a novel material technology able to integrate with surrounding tissue

kamari news

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

(18 Sep, 2022) Kamari Pharma announced the completion of an $8 million investment by the Chinese fund GIBF2.


Guangzhou Sino-Israel Biotech Investment Fund Completed a $ 4 Million Investment in the Israeli Subsidiary of CorNeat Vision

(11 Sep, 2021) Guangzhou Sino-Israel Biotech Investment Fund (GIBF) recently completed a $ 4 million investment in the Israeli subsidiary of Kornit Vision, which was established in Guangzhou, China.


GIBF (China-Israel) Fund Raised 300 million Dollars on the Second Fund

(31 May 2021) The Guangzhou Sino-Israel Bio-industry Investment Fund, headed by Israel’s former chief scientist, has already closed $200 million for its second fund to finance clinical trials.